Antimicrobials · Lipopeptides
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Daptomycin is a lipopeptide antibiotic that functions by inserting its lipid tail into the bacterial cell membrane, causing depolarization and rapid cell death.
Daptomycin provides excellent coverage against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Daptomycin is strictly contraindicated in pneumonia because it is inactivated by pulmonary surfactant.
Patients receiving daptomycin require routine monitoring of creatine phosphokinase (CPK) levels due to the risk of myopathy and rhabdomyolysis.
Daptomycin is a preferred alternative to vancomycin for complicated skin and soft tissue infections (cSSTI) and Staphylococcus aureus bacteremia.
Daptomycin is associated with a rare but serious risk of eosinophilic pneumonia, which typically presents with fever, dyspnea, and pulmonary infiltrates.
Daptomycin exhibits concentration-dependent killing and is administered via intravenous infusion.
Vignette unlocked
A 54-year-old male with a history of end-stage renal disease is hospitalized for a persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia despite adequate vancomycin trough levels. He is transitioned to an alternative antibiotic therapy. Three weeks later, he presents with diffuse muscle pain and weakness in his proximal extremities. Laboratory studies reveal a creatine phosphokinase (CPK) level of 12,000 U/L.
Which of the following medications is the most likely cause of this patient's clinical presentation?
Daptomycin
The patient's presentation of elevated CPK and myopathy is a classic side effect of daptomycin, which requires monitoring of muscle enzymes during therapy.
Full handout
High yield triage
Classification
Lipopeptide antibiotic; bactericidal against Gram-positive organisms.
Indications
MRSA skin/soft tissue infections and Staphylococcus aureus bacteremia.
Mechanism of Action
Inserts into the bacterial cell membrane, causing rapid depolarization and cell death.
Side Effects
Elevated creatine phosphokinase (CPK); myopathy and rhabdomyolysis.
Contraindications / Monitoring
Do not use in pneumonia; monitor CPK levels weekly.
Full handout
Mechanism of Action
Daptomycin binds to the bacterial cell membrane in a calcium-dependent manner. It causes rapid depolarization of the membrane potential, leading to inhibition of protein, DNA, and RNA synthesis. This results in bactericidal activity against resistant Gram-positive pathogens.
Unique Properties
Unlike vancomycin, daptomycin is rapidly bactericidal and does not require therapeutic drug monitoring. It is uniquely inactivated by pulmonary surfactant, rendering it ineffective for lung infections.
Indications
Indicated for complicated skin and soft tissue infections caused by susceptible isolates of Staphylococcus aureus (including MRSA). It is also a primary treatment for Staphylococcus aureus bacteremia, including right-sided endocarditis.
Pharmacokinetics
Daptomycin is administered via IV infusion only. It is primarily excreted by the kidneys; dosage adjustments are required for patients with a creatinine clearance <30 mL/min.
Side Effects & Adverse Events
Common side effects include gastrointestinal distress and headache. The most significant concern is myopathy and rhabdomyolysis, characterized by muscle pain and weakness. Patients may also develop eosinophilic pneumonia if treated for extended durations.
Contraindications
Do not use in pneumonia because the drug is inactivated by pulmonary surfactant. Use with extreme caution in patients taking HMG-CoA reductase inhibitors (statins) due to the increased risk of rhabdomyolysis.
Monitoring
Baseline and weekly creatine phosphokinase (CPK) levels are mandatory. If CPK rises to >5x the upper limit of normal in symptomatic patients, or >10x in asymptomatic patients, the drug must be discontinued.
Clinical Pearls
Boards often test the surfactant inactivation trap; never choose daptomycin for pneumonia. It is the preferred alternative to vancomycin when MICs are elevated or in cases of vancomycin-refractory MRSA.